MIM
GTBP icon

MetLife Investment Management’s GT Biopharma GTBP Stock Holding History

MetLife Investment Management’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-382
Closed -$178K – 2576
2021
Q2 		$178K Buy
+382
New +$159K ﹤0.01% 2238

Other funds holding GTBP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCP
Silverleafe Capital Partners Germantown, Tennessee $367M AUM 37.49% 1-Year Est. Return

MetLife Investment Management's GTBP Position: Q3 2021 in Review

MetLife Investment Management sold out of GT Biopharma (GTBP) in Q3 2021, closing a stake of 382 shares — an estimated $178K sold.

MetLife Investment Management first reported a position in GTBP in Q2 2021 and held it in 1 quarter. The position peaked at $178K in Q2 2021. 53 funds tracked by Wall St. Rank hold GTBP as of Q3 2021.

  • MetLife Investment Management reported no remaining GT Biopharma position as of Q3 2021 after selling out during the quarter.
  • MetLife Investment Management sold 382 GT Biopharma shares in Q3 2021, an estimated $178K.
  • MetLife Investment Management first reported a position in GT Biopharma in Q2 2021 and held it in 1 quarter.
  • MetLife Investment Management's GT Biopharma position peaked at $178K in Q2 2021.
  • 53 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2021.

Based on MetLife Investment Management's 13F filing for Q3 2021, filed 15 Nov 2021.